STOCK TITAN
  1. Home
  2. News
  3. PSNL

Personalis Inc - PSNL STOCK NEWS

Welcome to our dedicated news page for Personalis (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Personalis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Personalis's position in the market.

News
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Personalis, Inc. (PSNL) to Present at Needham Virtual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
conferences
-
News
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Personalis, Inc. (PSNL) to showcase NeXT Personal® assay data at AACR Annual Meeting, highlighting its potential in early cancer detection and therapy monitoring. Dr. Richard Chen, CMO, will present findings on ultra-sensitive ctDNA detection in melanoma and HCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
-
News
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) announces the validation of its NeXT Personal test, an ultra-sensitive circulating tumor DNA assay, designed to detect cancer recurrence early and improve patient outcomes. The study showcased high analytical sensitivity and specificity, paving the way for potential Medicare coverage. Initial findings at the ESMO Congress indicated improved detection rates in early-stage lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
News
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Personalis, Inc. (PSNL) granted non-qualified stock options to purchase 41,500 shares to ten new employees under its 2020 Inducement Plan. The options were granted on November 15, 2023, and March 15, 2024, with exercise prices of $1.11 and $1.61 per share, respectively. The options vest over four years, with 25% vesting on the first anniversary and the rest monthly, contingent on continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
none
-
News
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Personalis, Inc. (PSNL) reported strong financial results for Q4 and full year 2023, with revenue reaching $19.7 million and $73.5 million, respectively. The company highlighted key business achievements, including partnerships with Tempus AI, Myriad Genetics, and ClearNote Health. Personalis aims to focus on cancer types, generate clinical evidence, and accelerate commercialization in 2024. The net loss decreased to $26.6 million in Q4 2023, and the company projects a net loss of $80.0 million for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.16%
Tags
earnings
-
News
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Personalis, Inc. (PSNL) will release its Q4 and full year 2023 financial results on February 28, 2024. A conference call and webcast will follow to discuss the results and recent highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.46%
Tags
earnings
News
Personalis to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Personalis, Inc. (PSNL) will participate in investor conferences including BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference and 44th Annual Cowen Healthcare Conference. The company's management team will present at these events to engage with potential investors and showcase their advanced genomics for cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
-
News
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) has announced an alliance with ClearNote Health, Inc. to distribute ClearNote's epigenomic 5-hydroxymethylcytosine (5hmC) platform. This partnership aims to expand Personalis' pharmaceutical service offerings and accelerate revenue growth. The platform offers real-time insights into disease-specific pathways, early cancer detection, disease progression monitoring, and understanding of drug resistance mechanisms, contributing to more effective treatments for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.5%
Tags
partnership
-
News
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Personalis, Inc. (PSNL) announced the grant of non-qualified stock options to purchase 29,000 shares of its common stock to eight new employees under the 2020 Inducement Plan. The options were granted on January 15, 2024, with an exercise price of $1.74 per share. The options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 1/36th of the remaining shares vesting monthly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
none
News
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries. NeXT Dx analyzes a tumor’s entire exome and transcriptome to uncover deeper insights into therapy selection, including RNA-based fusions, tumor mutational burden, and microsatellite instability. The coverage for NeXT DX was extended effective August 29, 2023, under the Palmetto GBA MolDx program foundational Local Coverage Determination. Approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare. Personalis also recently launched the ultra-sensitive NeXT Personal Dx test for detecting molecular residual disease and cancer recurrence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
none
Stock PSNL logo
Personalis Inc

Nasdaq:PSNL

PSNL Rankings

#5474 Ranked by Market Cap
#4996 Ranked by Stock Gains
N/A Ranked by Dividends

PSNL Stock Data

65.29M
41.21M
0.82%
58.15%
2.14%
Medical Laboratories
Health Care and Social Assistance
Link
US
Menlo Park

About PSNL

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.